Welcome to our dedicated page for Nektar Therapeutics news (Ticker: $NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nektar Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nektar Therapeutics's position in the market.
Rhea-AI Summary
Nektar (NKTR) to present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 10, 2024. Webcast accessible via Nektar website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Nektar Therapeutics (NASDAQ:NKTR) announced that collaborators from the Cairo Laboratory at New York Medical College presented new preclinical data on NKTR-255 at the 65th American Society of Hematology (ASH) Annual Meeting. The data demonstrated that NKTR-255 significantly enhanced the cytotoxicity of expanded Natural Killer (NK) cells when combined with obinutuzumab against rituximab-resistant Burkitt Lymphoma (BL) cells and improved the survival of mice xenografted with Raji-4RH compared to controls. NKTR-255 is a novel polymer-conjugated human IL-15 receptor agonist currently being studied in three separate clinical studies in combination with cell therapies and immunotherapies. Preclinical and early clinical data suggest that NKTR-255 can improve proliferation and persistence of NK and CD8+ T cells to enhance specific anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.12%
Tags
-
Rhea-AI Summary
Nasdaq: NKTR - Nektar Therapeutics Reports Q3 2023 Financial Results, Initiates Phase 2b Studies, and Announces Clinical Study Collaboration with Cellular Biomedicine Group
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.09%
Tags
Rhea-AI Summary
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2023 on November 7, 2023. The conference call to review the results will be hosted by Howard Robin, President and CEO, at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The press release and webcast can be accessed through the Nektar website. The webcast will be available for replay until December 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
-
Rhea-AI Summary
Nektar Therapeutics presents new data for REZPEG at the 2023 EADV Congress, demonstrating dose-dependent efficacy and sustained benefit for patients with atopic dermatitis. The therapy shows potential to alter the need for frequent maintenance dosing and opens the door for a new therapeutic class.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
-
Rhea-AI Summary
Nektar Therapeutics to present Phase 1b data for REZPEG and Phase 2b study design at EADV Congress. Highlights potential as a remittive therapy for atopic dermatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
Rhea-AI Summary
Nektar Therapeutics partners with Cellular Biomedicine Group Inc. for a clinical study on NKTR-255 and C-TIL051 combination therapy in NSCLC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
-
Rhea-AI Summary
Nektar Therapeutics announces positive Phase 1b data for rezpegaldesleukin in atopic dermatitis, with LS mean % improvements in EASI score (83%), BSA (72%), DLQI (78%), and POEM (58%). Phase 2b study to start in October. Phase 2a study planned for alopecia areata in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
-
Rhea-AI Summary
Nektar Therapeutics to host virtual event on September 13 to discuss Phase 1b data of REZPEG in atopic dermatitis patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
Rhea-AI Summary
Nasdaq: NKTR - Nektar Therapeutics reports Q2 2023 financial results with $409.4 million in cash and securities, plans for rezpegaldesleukin Phase 2b study and IND filing in 2024. Revenue decreased to $20.5 million in Q2 2023. Operating costs and expenses decreased in Q2 and first half of 2023 due to lower R&D and G&A expenses, as well as restructuring and impairment costs. Net loss for Q2 2023 was $51.1 million, improved from $159.1 million in Q2 2022. Nektar announced promising new rezpegaldesleukin data and continues cost reduction initiatives and strategic partnerships evaluation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9%
Tags
Nektar Therapeutics
Nasdaq:NKTR
NKTR Rankings
NKTR Stock Data
336.03M
163.11M
0.82%
67.26%
1.28%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
SAN FRANCISCO
About NKTR
nektar therapeutics is a leading biopharmaceutical company developing a robust pipeline of novel therapeutics based on its advanced polymer conjugate chemistry technology platform. nektar also partners with the top biopharmaceutical companies to bring new products to market. to date, nektar's technology and drug development expertise have enabled nine approved products for partners, which include leading biopharmaceutical companies.